Qualgen LLC, Edmond, OK

Is Qualgen LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Qualgen LLC in Edmond, OK, first registered May 23, 2015 and most recently registered Dec 17, 2025.

Does Qualgen LLC hold a Oklahoma pharmacy license?

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023397 for QUALGEN LLC, EDMOND, OK, status INOPERATIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0004706 for QUALGEN, LLC (dba QUALGEN RX, LLC), EDMOND, OK, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0000065 for Qualgen, LLC, EDMOND, OK, status Active, as of Nov 10, 2026.

Has Qualgen LLC had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 4 Form 483s (latest Sep 4, 2025) for Qualgen LLC. State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search. The Maryland Board of Pharmacy’s posted orders against permit holders also lists “SUPPLEMENTAL CONSENT ORDER” dated Oct 22, 2024 on nonresident permit D05760.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Qualgen LLC
Location
Edmond, OK
Type as FDA labels it
503B
FDA 503B list
Listed as Qualgen LLC
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 4, 2025
FDA Data Dashboard inspections
6 inspections: 4 OAI, 2 VAI; 5 published Form 483s
Form 483 text on this page
5 Form 483s, 48 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Qualgen LLC, a 503B facility, with 5 dated actions.

Document
Sep 4, 2025Form 483483 Issued 09/04/2025fda.gov
Mar 19, 2024Form 483483 Issued 03/19/2024FDA copy (archived)
Dec 19, 2022Press release or statementFDA Press Release: Federal Court Enters Consent Decree Against Oklahoma Drug Compounder (12/19/2022)Not linked by FDA
Sep 30, 2022Form 483483 Issued 09/30/2022FDA copy (archived)
Jun 15, 2021Form 483483 Issued 06/15/2021fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Qualgen, LLC, Edmond, OK (FEI number 3011286349), matched to this page by exact name, city and state. It lists 6 inspections: 4 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 19, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30112863491230061
Sep 30, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30112863491180879
Jun 15, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30112863491144481
Sep 13, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30112863491067476
May 10, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30112863491014041
Sep 17, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011286349945189

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 48 numbered observations in all, across 5 inspections ending May 10, 2017 to Sep 4, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 19, 2025 to Sep 4, 2025: 5 observations

Firm on the cover
Qualgen, LLC, 14844 Bristol Park Blvd, Edmond, OK 73013-1891
FEI number
3011286349
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is insufficient physical or spatial separation from operations and other drug products to prevent mix-ups and cross-contamination.

Specifically,

Hazardous drugs were produced without appropriate containment, separation, and cleaning to prevent cross-contamination.

A) Th e <Redacted B4> ISO <Redacted B4> production rooms where testosterone and estradiol implantable pellets are manufactured are positive pressure to the shared ISO <Redacted B4> ante room where employees don and off gowning and PPE. The shared ISO <Redacted B4> ante room is not cleaned between production of testosterone and estradiol drug products in the aojoining ISO production rooms.

B) Your firm does not have documentation to demonstrate that the <Redacted B4> and <Redacted B4> cleaning agents used during <Redacted B4> cleaning of the ISO <Redacted B4> production rooms and ISO <Redacted B4> ante and prep rooms are effective for deactivation of hazardous drug residues such as testosterone and estradiol. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

***REPEAT OBSERVATION FROM INSPECTION CONDUCTED 2/6/2024 -3/19/2024***

Specifically,

A) Your procedure to document cleaning of <Redacted B4> Units is not fully followed. Your firm's procedure QG-1183, <Redacted B4> Cleaning and Storage" effective 1/13/2025, states that pre-use and post-use cleaning of the <Redacted B4> units by production employees should be documented and verified in your firm's <Redacted B4> Cleaning Logs, ELB-2025-009, at the time of completion of each cleaning activity. Video recording of production operations conducted on 8/11/2025 show production employees conduct the pre-cleaning anq post cleaning of the <Redacted B4> units but does not provide evidence to demonstrate that the <Redacted B4> cleaning was documented at the time of completion. Production employees verified the <Redacted B4> Cleaning Logs are not kept inside the classified rooms and therefore cannot be completed contemporaneously.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The quality control unit lacks responsibility to reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically,

Your firm failed to evaluate a HEPA filter in the ISO <Redacted B4> Testosterone cleanroom that was certified with no airflow. This room was certified in May 2025 and the certification report shows the <Redacted B4> HEPA filter was not providing any airflow. This room is designed with <Redacted B4> HEPA filters. Your firm's quality and production management were not aware that this HEPA filter was receiving no airflow and could not provide a date when the HEPA filter air supply was cut off. This room has been routinely used for granulation and compression of Testosterone since the certification on 5/02/2025. Your firm's last certification with a working <Redacted B4> HEPA filter in the Testosterone suite was 10/30/2024.

In addition, your firm's procedure QG-1256, "HEPA Filter Certification", effective 12/23/2024 rev. la states that "Any indication of poor air control (e.g., non-unidirectional, turbulent) must be corrected before use."

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

***REPEAT OBSERVATION FROM INSPECTION CONDUCTED 2/6/2024 -3/19/2024***

Specifically,

Your firm's revalidation of <Redacted B4> asset during sterilization of stoppers, <Redacted B4> performed on 5/1/2025, utilized in the container closure of vialed pellets did not meet the maximum load or time for the cycle used in production. Your firm's production oven cycle is <Redacted B4> stoppers across <Redacted B4> rays and <Redacted B4> shelves. The validated cycle is <Redacted B4> or <Redacted B4> stoppers across <Redacted B4> trays and <Redacted B4> shelves. In addition, your firm does not have load patterns documented in any procedure, work instruction, or pertaining material for new operators. The load pattern for stoppers is also not included in the revalidation protocol. Cycle parameters are also not verified by a second reviewer during production or batch review. The <Redacted B4> temperature and time are <Redacted B4> set by a single operator prior to each cycle run.

LJ

Observation 5

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and sampling plans designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A) Your firm's environmental monitoring alert and action limits are not scientifically justified. Your firm's procedure for environmental monitoring, QG-1 218, "Environmental Monitoring" effective 07/03/2025, states that the personnel fingertip sample alert and action levels in ISO - <Redacted B4> are ~2 CFU and ~5 CFU, respectively. Your firm's Director of Quality stated that these limits were taken from USP <1116> and USP <797>, however, your firm has not evaluated the suitability of those levels within your operations. For example, your firm recovered mold during personnel fingertip sampling but did not investigate or identify the recovered organism to the species level based on the action level. Estradiol 18mg, lot Kl 13, exp 4/14/2026 produced on 4/28/2025 had one mold CFU recovered from the glove of a production technician. ...

Read the full 483 (PDF on fda.gov)

Inspection Feb 6, 2024 to Mar 19, 2024: 14 observations

Firm on the cover
Qualgen, LLC, 14844 Bristol Park Blvd, Edmond, OK 73013-1891
FEI number
3011286349
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically,

b) Your firm is not always identifying all root causes of deviations and/or documenting the root cause for investigations. In addition, your firm does not always document within the investigation all issues/deficiencies/deviations related to the problem being investigated. Please refer to OBSERVATION 3 for details.

c) CAPA 22-0017 was created after the last inspection to address a 483 observation related to Work Orders not containing sufficient information regarding the activities/tasks performed. One action item listed is to perform an effectiveness check for 6 months to verify compliance with SOP QG-1158 Generating Work Orders. The results of the checks were to be attached to the CAPA. The checks were to be completed in May 2023. No documentation of the effectiveness checks was included in the CAPA and the CAPA was closed November 11, 2022. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

Specifically,

a) Your firm is not documenting and investigating all complaints received. For example, since the previous inspection in September 2022, your firm has received at least 23 reports of broken pellets that were not documented in your complaint handling system and investigated. This is a repeat observation from the 09/13-30/2022 inspection.

c) SOP QG-1069 Handling of Complaints. revision 10 effective November 7, 2023, requires complaints related to broken pellets be tracked and trended to detect any negative trends. Your firm is not tracking and trending all complaints per this SOP. Complaints reported in your Customer Complaint Log/Customer Complaint Logbook are the only complaints that are tracked and trended. In addition, when you are trending complaints of broken pellets, your firm is only looking at the number of complaints received and is not tracking and trending the number of broken pellets reported for a specific lot.

Observation 3

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your firm is not always identifying all root causes of deviations and/or documenting the root cause for investigations. In addition, your firm does not always document within the investigation all issues/deficiencies/deviations related to the problem being investigated. For example,

a) General Investigation Gl-23-050 initiated on June 8, 2023, was related to the use of a lot of Testosterone <Redacted B4> to make several lots of pellets before it had been approved/released by QA. The investigation noted the need to re-train <Redacted B4> production employees on the procedure related to proceeding at risk with production as well as good documentation practices for batch records. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

a) Your firm does not have a written procedure that defines when manufacturing equipment needs to be re-qualified. Since the previous inspection in September 2022, your firm has work orders and/or change controls related to replacement of parts such as the <Redacted B4> removing the <Redacted B4> from one press and installing on another, switching out and replacing <Redacted B4> from one press to another, and switching out the <Redacted B4> from one press to another and replacing it on one. Other maintenance and repairs performed were not fully documented. Most of this work required the removal of the pellet presses from the cleanrooms. Your firm has no documented evaluation of the maintenance, repairs and/or other work performed on the pellet presses to determine if a re-qualification and/or verification of the functioning of the pellet press needed to be performed after the maintenance and/or repairs. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, on February 13, 2024, I observed trays containing vials that had been <Redacted B4> sterilized uncovered and sitting inside one of the Biological Safety Cabinets (BSC) located in the Testosterone ISO 7 cleanroom. Per your Production Manager, the BSC was unplugged on January 26, 2024. No HEPA filtered air is supplied to the area within the BSC where the uncovered vials were stored before being used to vial lot # <Redacted B4> of <Redactted B4> mg Testosterone pellets.

Observation 6

There is a lack of written procedures providing cleaning schedules and describing in sufficient detail the methods, equipment and materials to be used for sanitation.

Specifically, your firm has no written procedure governing the entry of 3rd party personnel who perform activities such as room/hood certification and equipment calibration and qualification to enter the ISO 7/ISO 8 cleanrooms without being gown qualified. Your firm is not performing non-routine cleaning such as a <Redacted B4> clean after work is performed by these 3rd party personnel.

Observation 7

Routine calibration of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically,

Your firm is not bracketing the range of use when calibrating all equipment used in the manufacture of hormone pellets. For example,

a) Asset #220 -a balance used to weigh <Redacted B4> and pellet samples in the Estradiol cleanroom. For the E6mg Estradiol pellets, the required quantity of <Redacted B4> used weighs <Redacted B4> grams. For the calibrations performed on 07/15/2022 & 05/09/2023, the first test point is <Redacted B4> grams.

b) Asset #115 -balance used to weigh individual pellet weights in the Estradiol cleanroom. For E6mg Estradiol pellets, the specification for individual pellet weights is <Redacted B4> grams. For the calibration performed on 01/06/2023, the first test point as <Redacted B4> grams. For the calibration performed on 01/09/2024, the test points are <Redacted B4> and <Redacted B4> grams.

test point ~as (b)(4) grams. For the calibration performed on 01/09/2024, the test points are (b)(4) Iand I b}(4Y} grams. c) Asset #046 <Redacted B4> used to measure thickness of all Estradiol pellets. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Buildings used in the manufacturing, processing and packing of a drug product are not maintained in a good state of repair.

Specifically, there are areas of the flooring where the trim is not completely sealed in the ISO 7 Testosterone Room and ISO 7 Estradiol Room. This is where the flooring meets the window ledges. Repairs that have been made to the trim where the floor meets the window ledges do not always leave a smooth surface for cleaning. Black smudges were also seen on the floor or the ISO 7 Estradiol Room that may have originated from the wheels of the chairs in the clean room. There is also some chipped paint on one of the legs of the BSC in the ISO 7 Estradiol Room.

Observation 9

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

a) On February 13, 2024, we observed rust on the backside of the <Redacted B4> located in the ISO 8 Prep Room. There are <Redacted B4> that are <Redacted B4> and scratches on the top of the <Redacted B4> and some debris <Redacted B4> could be seen. The <Redacted B4> are used to sterilize. <Redacted B4> glass vials and to sterilize rubber stoppers.

b) Scratches and dents could be seen in the metal surface of the base used to hold the small <Redacted B4> lender (area just below the blender) used for the mixing of the Testosterone <Redacted B4> Anastrozole, and stearic acid to make Testosterone 200mg/Anastrozole 20mg pellets.

Observation 10

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.

Specifically, your firm is not including the Testosterone/Cholesterol pellet in your <Redacted B4> audits. Your firm has no documentation of an assessment conducted to determine the product family for this pellet which was introduced in 2020. Your Testosterone/Cholesterol Sterilization and Sterility Validation performed in 2020 states under the Scope of the protocol that the <Redacted B4> sterilization process is to be validated for the Testosterone/Cholesterol Drug Pellet Family. There is no further documentation of a determination of the product family for this product.

Your firm has no procedure requiring a product family assessment be performed for each new product to be <Redacted B4> sterilized. Criteria for defining a product family and assessment against the criteria are not defined and documented.

Observation 11

The batch production and control records are deficient in that they do not include complete labeling control records, specimen and copy of labeling.

Specifically,

a) Your firm does not include in the batch record an example/copy of the secondary packaging labeling (box). This is a repeat observation from the 09/13-30/2022 inspection.

b) SOP QG-1273 PQ§t Batch Release Splitting or Combining of 12, and JQ Packs including ~ecQndar:i Labeling Reguirements within a Single of revision effective January 23, 2024 describes the "steps to be performed when a released batch requires splitting or combining of 6, 12, or 30 oacks. including issuance of new secondary labeling, in order to follow the <Redacted B4> method of inventory control or when Operations/Logistics determines it is necessary to fulfill an order''. Your firm is not maintaining a copy of the new secondary labeling generated as a result of this procedure. Lot number 4(b)() of T87.5mg Testosterone pellets released on January 10, 2024 is an example (packs split on January 25, 2024 ).

Observation 12

Procedures describing in sufficient detail the controls employed for the issuance of labeling are not written and followed.

Specifically, your firm does not have a written procedure for the receipt, approval, issuance, use and reconciliation of the secondary packaging containers (boxes) used for all hormone pellets.

Observation 13

Master production and control records lack a description of the drug product containers, closures and packaging materials.

Specifically, your firm is using a <Redacted B4> insert for T87.5mg and T100mg Testosterone pellets packed into 30 count boxes. Batch record BR-0020 Pellet Packaging Record does not reference the use of the <Redacted B4> inserts. During packaging operations, the production technician refers to an uncontrolled document that instructs them to use the <Redacted B4> inserts for these specific pellet strengths and quantities.

Observation 14

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically,

a) Your firm has no written procedures that require personnel who perform visual inspection to be periodically re-qualified. Production Technician <Redacted B4> was initially qualified for visual inspection on August 3, 2021. He continued to perform visual inspection activitiest,, including training of new employees, until July 31, 2023. Production Technician <Redacted B4> was initially qualified for visual inspection on August 12, 2021. He continued to perform visual inspection activities until July 14, 2023. At no time during the nearly two (2) years these two (2) employees performed visual inspection were they re-qualified.

b) Your firm has <Redacted B4> that is used for the qualification of personnel to perform visual inspection. The <Redacted B4> does not contain examples of all types of defects currently identified such as loose caps, glass inside vial, and pellet not well compressed (looks like <Redacted B4>). ...

Read the full 483 (PDF on fda.gov)

Inspection Sep 13, 2022 to Sep 30, 2022: 9 observations

Firm on the cover
Qualgen, LLC, 14844 Bristol Park Blvd, Edmond, OK 73013-1891
FEI number
3011286349
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
1201 Main St reet, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

a) Quality Assurance (QA) <Redacted B4> Work Orders per SOP QG-1158 Generating Work Orders, revision O effective June 29, 2021. In addition, the system for documenting Work Orders is deficient. For example, Work Orders do not always contain sufficient information regarding the activities/tasks actually performed. Proposed solutions are sometimes noted in the Work Order however, your fnm does not always document if the proposed solution was performed and/or what other tasks were performed to complete the Work Order. For example, Work Order <Redacted B4> as opened and closed on June 17, 2022, states the <Redacted B4> has a 1X 1 inch area under paint that is corroded. In speaking to the QC employee who opened and closed the work order, the proposed solution was not performed and instead the blower was removed from the unit. This was not documented in the work order. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Written procedures are not followed that describe the examinations to be conducted on appropriate samples of in-process materials of each batch.

Specifically,

Your firm is not conducting an AQL sampling and inspection of vials (hormone pellets) after <Redacted B4>

Observation 3

Drug products failing to meet established specifications are not rejected.

Specifically,

Your firm's SOP entitled, "Release or Rejection of Sterile Pellet Drug Products and Specifications" Document G-1144 Effective 17 August 21 states that <Redacted B4>. However, On February 11, 2022 your firm's Quality Control Unit approved and released a lot of Testosterone/Cholesterol 200mg sterile pellets, Lot <Redacted B4> that failed thickness, a release specification. This lot was distributed to several states.

Observation 4

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

Specifically,

Your firm does not follow your SOP entitled, "Handling of Complaints" QG-1069, Revision 5, Effective 17 Jun 22, regarding how to receive, document and conduct complaint investigations. There were consumer complaints that did not have a conclusion, were not properly documented, not adequately investigated, and/or have not been closed <Redacted B4> from initial complaint receipt. For example,

• Complaint CIN-22-012 dated April 7, 2022 stated that five patients from one clinic had infection after the implantation of your firm's Testosterone/Cholesterol pellets, Lot <Redacted B4> and <Redacted B4>. Your firm's investigation did not document the conclusion/outcome in the customer inquiry /complaint record but was closed by QA on June 29, 2022.

• Complaint CIN-22-036 received July 15, 2022: Your firm received an email from the complainant asking to speak to someone about a potential problem with pellets from your firm. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.

Specifically,

a) Your firm uses Testosterone API from <Redacted B4> different manufacturers to make hormones pellets. Your firm has no documented justification for not including in each <Redacted B4> dose audit/bioburden testing lots of Testosterone pellets made with Testosterone API from each manufacturer.

b) Your firm uses <Redacted B4> to communicate with your technicians located in the cleanrooms during the production of hormone pellets that are charged and stored in an unclassified area. On 9/14/2022, we observed a technician <Redacted B4> the <Redacted B4> with <Redacted B4> but fail to fully wipe down the headphones to ensure it was appropriately disinfected prior to entry from an unclassified area to the ISO8 anteroom. Furthermore, your firm has not determined if the <Redacted B4> used to disinfect the <Redacted B4> is suitable for use in disinfecting the <Redacted B4>

Observation 6

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm conducts potency testing <Redacted B4> of our hormone pellets containing estradiol or testosterone in house. The test methods require the use of <Redacted B4> as a reagent for the <Redacted B4> solution needed to perform the test however, our firm is not using pharmaceutical or laboratory grade <Redacted B4> instead our firm is using <Redacted B4> brand <Redacted B4>. There is no assurance that the <Redacted B4> brand <Redacted B4> is suitable for its intended use.

Observation 7

Written procedures are lacking for the use of cleaning and sanitizing agents designed to prevent the contamination of equipment.

Specifically,

On 9/13/2022 and 9/14/2022, we observed the top of a container of <Redacted B4> wipes left open in the ISO 8 anteroom after the technician was finished gowning. The container was closed as soon as we mentioned it to your firm. However, on 9/15/2022, the same container top was left open for at least <Redacted B4>. Your firm uses <Redacted B4> wipes to disinfect the <Redacted B4> located in the ISO 8 anteroom and to disinfect the <Redacted B4> that technicians don over their sterilehood prior to entiy into the ISO7 rooms used in the production of hormone pellets. Your firm does not document the lot number of the wipes on cleaning logs. Furthermore, your firm has not established a use by date of the <Redacted B4> wipes after opening of the container.

Observation 8

Batch production and control records do not include complete information relating to the production and control of each batch.

Specifically,

Your firm's batch production records for your hormone pellets are deficient in that:

a) Active Pharmaceutical Ingredients (API) such as Testosterone, Estradol and/or Anastiozole ai·e not properly weighed out during the <Redacted B4> instead a <Redacted B4> is used to measure out the API used in each <Redacted B4> batch.

b) Batch production records do not include complete labeling including specimens or copies of all labeling used for each batch of drug product produced. For example, your firm does not include an example/copy of the <Redacted B4> packaging labeling.

c) No documentation or justification of established production time liinit deviations. For example, your fnm has established a production limit of <Redacted B4> and <Redacted B4> for the production of Testosterone Pellets 200mg however, Lot <Redacted B4> exceeded this timeframe and there was no explanation found on the batch production record.

found on the batch production record.

Observation 9

The labels of your outsourcing facility's drug products are deficient.

Specifically,

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically, the following information is not found on your drug product labels:

a. The quantity or volume.

Examples of your drug product labels that do not contain this information:

Estradiol 6mg Pellet,

Estradiol 25mg Pellet,

Testosterone 25mg Pellet

Testosterone 200mg Pellet

Inspection Apr 29, 2021: 15 observations

Firm on the cover
Qualgen LLC, 14844 Bristol Park Blvd., Edmond, OK 73013
Establishment type on the cover
Outsourcing Facility THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION. OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION. YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.
FDA district office on the cover
One Main Place 1201 Main St., Suite 7200 Dallas, TX 75202
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closure, in-process materials, packaging materials, labeling, and drug products. The responsibilities and procedures applicable to the quality control unit are not in writing or fully followed.

Specifically,

a) On March 1, 2021, your firm began distribution of lot <Redacted B4> of Testosterone Cypionate Injection 200mg/mL, labeled as a multi dose vial, before the results of the antimicrobial effectiveness test were received. The expiration date placed on the product was 17MAR21. On March 2, 2021, your contract testing lab notified your firm of a potential failure of the antimicrobial effectiveness test for the product. Your firm continued to distribute the lot until March 12, 2021. On March 16, 2021, your contract testing lab sent an email confirming failure of the antimicrobial effectiveness testing. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written or followed.

Specifically,

a) Your firm has no written procedures for conducting the <Redacted B4> test on <Redacted B4> Testosterone Cypionate Injection 200mg/mL, including lot <Redacted B4> that was compounded, <Redacted B4> and vialed on January 16, 2021.

:J

b) The process of removing cleanroom goggles due to fogging and the steps that should be taken by the technicians to deal with this issue are not defined in a written procedure.

c) On April 30, 2021, I saw a technician <Redacted B4> leave the ISO 7 <Redacted B4> Cleanroom, remove <Redacted B4> goggles in the ISO 8 Ante Room, dry goggles in the air coming from the door to the ISO 7 6 4 Room, place the goggles back on <Redacted B4> face, re-enter the ISO 7 <Redacted B4> Cleanroom without changing or spraying <Redacted B4> gloves, and then proceed to place a stainless steel cup used for pellets under the ISO 5 hood. The same technician left the ISO 7 <Redacted B4> Cleanroom several more times to clear <Redacted B4> goggles that were fogging up. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There are no written methods of cleaning or methods of processing to remove pyrogenic properties.

Specifically, your firm does not have a procedure for the sterilization/depyrogenation of glass beakers and cylinders and other utensils such as the <Redacted B4> used in the compounding of Testosterone Cypionate Injection. Your firm has no documentation to show that the glass beakers and cylinders and <Redacted B4> used in the production of lot <Redacted B4> of Testosterone Cypionate Injection 200mg/mL on January 16, 2021 had been sterilized/depyrogenated before use.

Observation 4

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically,

b) < Re dac ted B 4> an d <Redacted B4> used to make hormone pellets were found to have scratches, rust and/or d iscoloration. <Redacted B4> for Testosterone 50mg. <Redacted B4>, Lower <Redacted B4> <Redacted B4> and Upper <Redacted B4> <Redacted B4> for Testosterone 100mg <Redacted B4>, Upper <Redacted B4> and Redacted <Redacted B4> for Testosterone 100mg Examples include: There is no written procedure for <Redacted B4> the <Redacted B4> or <Redacted B4> and no documentation when specific <Redacted B4> or <Redacted B4> are <Redacted B4>.

ak e hor mone pel lets w er e

<Redacted B4> and <Redacted B4> used to m

fou nd to ha ve scratc hes, rust and/ o r dis coloration. < Redac ted B4> for Testosterone 50mg. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Changes to written procedures are not reviewed and approved by the quality control unit.

Specifically, your firm does not always document review and approval of changes prior to implementation. SOP QG-1129 cGMP Change Control, revision 3 effective September 2, 2020, states that "cGMP systems, processes, methods, materials, equipment, facilities, utilities, or documents may not be changed without a formal change control process done according to this procedure".

Examples of changes made without a change control include the following.

III. At some point in January 2021, your firm implemented parametric release of sterile drug products (hormone pellets) without a change control. Requirements for validation, including protocols, <Redacted B4> dose audit requirements, procedures and other process controls and parameters were not defined and laid out in a change control.

IV. In April 2021 , your firm made a change to the visual inspection program for sterile hormone pellets that was not implemented via a change control. You changed the requirement for visual inspection of pellets post vialing from 100% inspection to an <Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

b) On April 30, 2021, I saw a technician working in the ISO 8 Prep Room preparing stoppers for sterilization, with hair coming out of <Redacted B4> hairnet.

Observation 7

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

a) Your firm has not evaluated whether not drying the testosterone reference standard as noted in the directions on the certificate from USP, has any effect on the assay testing performed on testosterone hormone pellets.

b) Your firm has no documentation for the validation of the endotoxin method used for the testing of the Testosterone Cypionate Injection 200mg/mL.

Observation 8

The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.

Observation 9

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design or suitably located to facilitate operations for its cleaning and maintenance.

Specifically,

a) There are <Redacted B4> hoods in the <Redacted B4> ISO 7 Cleanroom. <Redacted B4> Biological Safety Cabinet (BSC) <Redacted B4> Laminar Flow Hood (LFH). <Redacted B4> BSC was moved to it's current position to accommodate the <Redacted B4> LFH used for the compounding of Testosterone Cypionate Injection. The outlet needed to plug in equipment such as the non-viable particle counter and <Redacted B4> used for Estradiol granulation, is now behind <Redacted B4> BSC. The gowned operators are not able to plug in the equipment without rubbing their gown against the wall of the cleanroom and/or the side of <Redacted B4> BSC. We observed the operator plugging in the NVP counter on various dates including May 4, 2021. SOP QG-1096 Aseptic Processing, revision 5 effective July 2 J, 2020, states under section 8.1.2 that <Redacted B4> PPB is defined as "Personal Protective Equipment which is worn to protect the aseptic environment from normal human flora". ...

Read the full 483 (PDF on fda.gov)

Observation 10

Drug product closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically, your firm has not conducted a hold time study to justify the use of sterilized stoppers for vialing of hormone pellets beyond the date of sterilization. Examples of stoppers being used days after sterilization while being stored in an ISO 8 Prep Room include the following:

a) Lot # <Redacted B4> of Testosterone 87.5mg pellets -the rubber stoppers used were sterilized on 11/23/2020 and 12/04/2020 and used in the final product vialing on 12/09/2020.

b) Lot <Redacted B4> of Testosterone 50mg pellets-the rubber stoppers used were sterilized on 12/04/2020 and used in the final product vialing on 12/12/2020.

c) Lot <Redacted B4> of Testosterone 25mg pellets-the rubber stoppers used were sterilized on 11/25/2020 and used in the final product vialing on 12/14/2020.

d) Lot <Redacted B4> of Estradiol 18mg pellets the rubber stoppers used were sterilized on 12/09/2020 and used in the vialing of final product on 12/14/2020. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations.

a) WO # 10-23-19-01 created on 10/23/2019 order to re-caulk/re-seal base and top boards and some ceiling tiles in the cleanrooms

b) WO #11-12-19-02 created on 11/12/2019 -ceiling above the BSC in the <Redacted B4> room needs to be replaced

c) WO #06-10-20-02 (date created is not documented but the issue was observed April 30, 2020 that led to the creation of the WO) -''yellow painted brackets in <Redacted B4> chipping"

Observation 12

Routine calibration of automatic, mechanical, and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, balances used for in-process weight checks, finished product release, and finished product release testing are not calibrated bracketing the range of use. The first test point after zero is <Redacted B4> or <Redacted B4>. The maximum weight of any pellet is <Redacted B4>.

Observation 13

The master production and control records are deficient in that they do not include complete manufacturing and control instructions and procedures.

Specifically, the current versions of the batch record for granulation of testosterone to be used in all testosterone pellets, does not reflect the current process. The batch records state that you are using an <Redacted B4> instead of the <Redacted B4> that was put into production in December 2020. The operators are making <Redacted B4> changes to the batch record to reflect the use of the <Redacted B4> however, the batch records lack certain infonnation regarding the operations of the <Redacted B4> such as the speed the equipment is to be set at for granulation that was contained in previous versions of the batch record.

Observation 14

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l 0) (A). Specifically, the following information is not found on your drug product labels:

A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.

Examples of your drug product labels that do not contain this information:

a. Testosterone 200mg/ Anastrazole 20mg Pellets

Per section 503B(a)(l0)(B)(i), this information should be included in/on the container ifthere is no space on the label for such information.

Observation 15

The containers of your outsourcing facility's drug products does not include information required by section 503B (a)(l0)(B). Specifically, your containers do not include the following information:

A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.

b. Testosterone 200mg/ Anastrazole 20mg Pellets

Inspection Apr 17, 2017 to May 10, 2017: 5 observations

Firm on the cover
Qualgen, LLC 14844 Bristol Park Blvd
FEI number
3011286349
Establishment type on the cover
Outsourcing Facility Edmond, OK 73013-1891
FDA district office on the cover
Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of i ts components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

a) Your firm ha s ha d five (5 ) st erility failures in 2016 (lot #B020 Testosterone 20 0mg pe llets, lo t #B 054 Estradiol 6mg pellets) and two (2) in 2017 (lot #C008 of Testosterone 200mg/20mg pellets and lot #C0 48 of Estradiol 18mg pellets) . Y our inve sti gatio ns do not a lwa ys include a documented r eview of all pot ential it ems that ma y hav e contribu ted to these failures , f or e xample environm ental and per sonnel monitor ing, engineering controls and the use non-validated processes. This is a repeat observation from the 8/24/15 - 9/17/15 inspection.

Your firm has had five (5) sterility failures in 2016 (lot #B020 Testosterone 200mg pellets, lot #B054 Estradiol 6mg pellets) and two (2) in 2017 (lot #C008 of Testosterone 200mg/20mg pellets and lot #C048 of Estradiol 18mg pellets). ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

Specifically,

a) Your firm lacks documentation to show that the process for the sterilization of all pellet products

via <Redacte d B4> has been validat ed. Specifica lly, the report for <Red ac ted B4> dated 5/19/15 for th e <Redacted B4> sterilization validation from your 3rd party vendor tha t perform s the <Redacted B4> sterilization process, was performed using <Redacted B4>.

b) The most recent smoke studies conducted on the ISO 5 <Redacted B4> loc ate d in <Re dact ed B4> ISO 7 c leanroom < Reda cted B4>) are not r epr esent ative of your current operations. Specifically, on various dates throughout this inspectio n, your firm h ad <Red ac ted B4>. Moreover, the following mater ials were ob serv ed in the h ood while thi s pr ocess was

ongoing: <Redacted B4> pans of depyrogenated vials (each oan contain s approxi mately <Re dacted B4> vials), <Redacted B4> piles of stop pers (each pil e con tai ning approx imately < Red acted B4> stoppers), ...

Read the full 483 (PDF on fda.gov)

Observation 3

The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.

Specifically,

a) During re-certification of the clean rooms and ISO 5 < Reda cted B4>, a leak was detected in one of the HEPA filoters in the <Redacted B4> (Lab

<R ed acted B4> The report

from the 3rd party vendor does not mention the leak, identi fy which HEPA fi lter was leaking, the fact that the HEPA was changed, or the fact that they did not perform certification of the rooms or hoods on that date due to t he leak. They returned on <Redacted B4> to certify the rooms and hood s after the HEPA filter wa s replaced. A <Redacted B4> HEPA filter was found to be leaking when they return ed on <Reda cted B4> to perform a clean room certificat ion after <Red acted B4> . The r epor t does not ment ion th e lea k, iden tify which HE PA filt er wa s lea kin g, o r the fact that it was changed.

r

b) Personnel performing fingertip sampling after working in the ISO 5 <Redacted B 4> we re observ ed lightly touching <Redacte d B4> of their glo ves to the pl ate dur ing finger tip monitori ng. The sampling does not include the pad of the finger. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Written procedures are not established and followed that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.

Specifically,

a) Your firm has no written justification for the sample sizes for in-process testing of <R edacted B4> and cannot demonstrate that they were established using suitable statistical procedur es.

Your f irm <Re

da cted B4> for < Redacte d B 4>. Theoretical batch sizes ar e <Reda cted B4> pellets depending on the

product. This is a repeat observation from the 8/24/15 - 9/17/15 inspection.

b) Y our firm h as stopped documenting in the batch record for all Testosterone pellets the actual in-p

rocess individual pellet weight values obtained. F or all testosterone drug products produced, t he <Redacted B4> pellets that are determined by the operat or <Reda ct ed B4> and those results are not documented.

Observation 5

Each batch of drug product required to be free of objectionable microorganisms is not tested through a ppropriate laboratory testing.

Specifically,

a. The sterility test method used by your current 3rd party vendor for release testing of finished drug products is not validated. The pieces ofThe sterility test method used by yo ur current 3rd party v endor for rel ease testing of finished drug products is not validated. The pieces of pellet that did not dissolve during the incubation period of dissolved late in the incubation period were not adequately incubated for the sterility test.

b. The sterility test method used during the validation a nd <Redacted B4 > fo r the <Red acted B4> sterilization process is not validated. The pieces of pellet that did not dissolve during the incubation period of dissolved late in the incubation period were not adequately incubated for the sterility test.

c. The bioburden determination for validation of the sterilization process was not performed using product from your firm. With regards to the method used to determine bioburden, the <Redacted B

4> may not recover the bioburden in the whole pellet.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Oklahoma are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its license lookup is an interactive search.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054023397LICENSED PHARMACYQUALGEN LLCEDMOND, OKINOPERATIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0004706NONRESIDENT PHARMACYQUALGEN, LLC (dba QUALGEN RX, LLC)EDMOND, OKACTIVE (CURRENT)

Maryland Board of Pharmacy, board actions read Nov 15, 2026 (Maryland).

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000065Outsourcing Facility-DistributorQualgen, LLCEDMOND, OKActive

FDA’s 503B list

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.